IGMPI facebook News
IGMPI Logo
Faculty of Pharmaceutical Sciences

(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)

ADMISSIONS NOTICE
18001031071 (Toll Free), +91 11 26512850
Regular Classroom | Online Mode
Stanford study highlights glucose's surprising role in cell differentiation
Stanford study highlights glucose's surprising role in cell differentiation
Cargill Kitchen Solutions Recalls 212,268 Pounds of Liquid Egg Products
Cargill Kitchen Solutions Recalls 212,268 Pounds of Liquid Egg Products
Recall Alert: Nissin Big Cup Noodles Recalled for Undeclared Allergens
Recall Alert: Nissin Big Cup Noodles Recalled for Undeclared Allergens
FDA Expands Warning on Frozen Oysters Linked to Norovirus Outbreak
FDA Expands Warning on Frozen Oysters Linked to Norovirus Outbreak
WHO Publishes 12th Edition of The International Pharmacopoeia
WHO Publishes 12th Edition of The International Pharmacopoeia
States Move to Restrict Synthetic Food Dyes Over Health Concerns
States Move to Restrict Synthetic Food Dyes Over Health Concerns
Iowa Senate Approves Bill Shielding Pesticide Companies from Lawsuits
Iowa Senate Approves Bill Shielding Pesticide Companies from Lawsuits
Growing Backlash Against Human Waste Fertilizer Over PFAS Contamination
Growing Backlash Against Human Waste Fertilizer Over PFAS Contamination
Cassava Sciences Ends Simufilam Development After Phase III Failures
Cassava Sciences Ends Simufilam Development After Phase III Failures
Axsome’s Sunosi Shows Promise in Phase III ADHD Trial
Axsome’s Sunosi Shows Promise in Phase III ADHD Trial
Wave Life Sciences’ WVE-N531 Shows Promise in Duchenne Muscular Dystrophy (DMD) Trial
Wave Life Sciences’ WVE-N531 Shows Promise in Duchenne Muscular Dystrophy (DMD) Trial
FDA Warns Chara Biologics Over Unapproved and Adulterated Products
FDA Warns Chara Biologics Over Unapproved and Adulterated Products
EU Launches PFAS Reduction Project in Healthcare
EU Launches PFAS Reduction Project in Healthcare
Equillium’s Itolizumab Misses Primary Endpoint in Phase III Trial but Seeks Breakthrough Therapy Designation
Equillium’s Itolizumab Misses Primary Endpoint in Phase III Trial but Seeks Breakthrough Therapy Designation
IGC-AD1 Shows Promise for Alzheimer’s-Related Agitation in Phase II Trial
IGC-AD1 Shows Promise for Alzheimer’s-Related Agitation in Phase II Trial